Deep-tech life growth solutions firm Acculi Labs has raised $1.5 million in a fresh investment round led by Sabi Holding India Ltd., valued at $25 million.
The Bengaluru-based business had previously raised Rs 5 crore in 2020 during a seed funding round that was directed by PirE Ventures.
According to a press statement from Acculi Labs, the new cash will be used to boost workforce, operational effectiveness, infrastructure development, and the speed at which its conscious AI insights solutions are developed.
Acculi Labs, co-founded in May 2017 by Rupam Das and Hari Prasath M, intends to provide patients with access to home-based care. Lyfas, the company’s flagship product, helps early-stage asymptomatic patients see their doctor sooner by facilitating simple, routine early testing and monitoring.
Read also- Dubai-Based Meta has Partnered with Startupbootcamp to Support MENA Startups
Acculi Labs claims that with the introduction of Lyfas, their product line grew from a single cardiac health assessment system to a whole range of healthcare solutions.
Read also- India-Based Square Insurance has Raised $3 Million in Pre-Series A Round Funding
The platform states that it can obtain psychophysiological indicators non-invasively with its mobile application and provide a comprehensive health assessment in three minutes.
The business created Lyra, a state-of-the-art conscious AI that connects silicon and carbon-based life forms. Additionally, it has introduced the Lyfas Udyam initiative, which offers small business owners a micro-enterprise circular economy through which they may start and manage their enterprises by utilizing the ecosystem, procedures, and funding.
About Acculi Labs
Lyfas is a digital biomarker, diagnostic, and prognostic tool that was created using the photoplethysmography (PPG) basis. It measures variations in blood volume and the blood chemistry’s reflected light spectrum in the tissue’s microvascular bed.
